ClinicalTrials.Veeva

Menu

Pharmacokinetics of Meropenem During High-dose CRRT

M

Medical University of Lublin

Status

Completed

Conditions

Infection
Renal Failure

Treatments

Drug: Meropenem
Device: CRRT

Study type

Observational

Funder types

Other

Identifiers

NCT03507751
90/2009/IV

Details and patient eligibility

About

Assessment of meropenem plasma concentration in critically ill patients who require CRRT (continuous renal replacement therapy). A standard dose of meropenem is administered, i.e. 1 gram every 8 hours.

Full description

This is a prospective observational study performed on critically ill patients. Inclusion criteria are a severe infection on admission requiring the use of meropenem and CRRT.

Both medical and surgical patients will be included. Any type of infections can be included (pulmonary, abdominal, urinary tract, etc.) Antibiotics regimen includes one-hour infusion of meropenem (1.0 gram) intravenously every 8 hours.

Blood samples (2 mL) will be collected at the 15, 30, 45, 60, 75, 90, 120, 180, 240, and 480 minutes after each dose of meropenem for 3 consecutive days. The standard arterial canula will be used to obtain samples.

30 minutes after each sample collection, blood will be centrifuged for 10 minutes at 3,000 rpms. Subsequently, supernatant will be collected and frozen.

Serum meropenem concentration will be measured by high-performance liquid chromatography.

Each patient's hemodynamic parameters will be recorded with the use of transpulmonary thermodilution technique (PICCO). Other therapies, i.e. ventilatory support, sedation, an antifungal agent will be given as required.

Enrollment

19 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who require ICU treatment due to severe infection
  • age 18-80 years
  • an eligible consent obtained from the patient or his/her attendant

Exclusion criteria

  • allergy to meropenem
  • lack of consent to participate in the study
  • age of patients below 18 or above 80 years

Trial design

19 participants in 1 patient group

Meropenem
Description:
Patients who require meropenem and CRRT during ICU (intensive care unit) stay
Treatment:
Drug: Meropenem
Device: CRRT

Trial contacts and locations

1

Loading...

Central trial contact

Michał Borys, M.D., Ph.D.; Mirosław Czuczwar, M.D., Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems